CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results
MT Newswires Live
Sep 24
CSPC Pharmaceutical Group's (HKG:1093) phase III trial of Becotatug in combination with osimertinib met its primary endpoint at a pre-specified interim analysis and achieved positive topline results.
The drug combination was being tested for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Compared with platinum-based chemotherapy in combination with pemetrexed, the treatment combination significantly prolonged the progression-free survival of patients and showed a trend of benefit in overall survival.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.